Skip to main content
Patricia Devine

Featured Patient Story

Patricia Devine

read more

Latest News Story Headlines

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

CAMBRIDGE, Mass., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.

read full article
2024 Fall Newsletter
Be sure to catch up on the latest happenings in our fall newsletter.
read full article
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug.

read full article

Calendar & Upcoming Events

Giving Tuesday

2024 Giving Tuesday

view all event details

Webinar: Grace vs. Forgiveness

Webinar Session, Wednesday, Dec. 4th, 2024 at 6 PM (ET)

view all event details

Amyloidosis Videos

Our Latest Webinar

Updates in AL amyloidosis: Fast Forward in 2024!

Heather Landau, MD - Memorial Sloan Kettering Cancer Center - New York, NY

Sign Up for the Latest Updates

Get news from Amyloidosis Foundation
in your inbox

By submitting this form, you are consenting to receive marketing emails from : Amyloidosis Foundation, 7151 N. Main St., Suite 2, Clarkston, MI, 48346, US, https://www.amyloidosis.org. You can revoke your consent to receive emails at any time by using SafeUnsubscribe© link, found at the bottom of every email. Emails are serviced by Constant Contract.